Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.0%

2 terminated out of 20 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

22%

2 of 9 completed with results

Key Signals

2 with results82% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (11)
P 1 (2)
P 2 (4)
P 3 (1)

Trial Status

Completed9
Unknown3
Active Not Recruiting3
Withdrawn2
Terminated2
Recruiting1

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT04519619RecruitingPrimary

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

NCT07201415Not ApplicableActive Not RecruitingPrimary

Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma

NCT07177807CompletedPrimary

Clinical Characteristics of Neovascular Glaucoma

NCT05316142Not ApplicableActive Not RecruitingPrimary

Effect of Subconjunctival 5-fluorouracil on the Outcome of Ahmed Valve in Neovascular Glaucoma

NCT04844619Phase 1Active Not RecruitingPrimary

KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial

NCT02260219Not ApplicableTerminatedPrimary

Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma

NCT05156021Not ApplicableCompletedPrimary

A Study on the Treatment Strategy of NVG Secondary to PDR

NCT02805257Phase 2Completed

Ahmed Glaucoma Valve Surgery With Mitomycin-C

NCT01711879Not ApplicableCompletedPrimary

Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma

NCT04970251Not ApplicableCompleted

Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

NCT00727038Phase 1Withdrawn

Lucentis for New Onset Neovascular Glaucoma

NCT03154892Not ApplicableCompletedPrimary

The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma

NCT00524758Phase 3Completed

Oculusgen (Ologen) Glaucoma MMC Control in Estonia

NCT02067013Phase 2Unknown

Analysis of Aqueous and Vitreous Humor

NCT01301378Not ApplicableTerminated

Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube

NCT02947867Phase 2Unknown

Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG

NCT01370135Not ApplicableCompletedPrimary

Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma

NCT00441181Not ApplicableWithdrawnPrimary

Effects of Travoprost on Neovascular Glaucoma

NCT01051583Phase 2CompletedPrimary

Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma

NCT00491712Not ApplicableUnknownPrimary

Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection

Showing all 20 trials

Research Network

Activity Timeline